Gillery Philippe
Laboratory of Biochemistry-Pharmacology-Toxicology, Biology and Pathology Department, University Hospital of Reims, Reims, France.
Laboratory of Medical Biochemistry and Molecular Biology, UMR CNRS/ URCA n°7369, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France.
Clin Chem Lab Med. 2022 Oct 14;61(5):861-872. doi: 10.1515/cclm-2022-0894. Print 2023 Apr 25.
Since its discovery in the late 1960s, HbA has proven to be a major biomarker of diabetes mellitus survey and diagnosis. Other biomarkers have also been described using classical laboratory methods or more innovative, non-invasive ones. All biomarkers of diabetes, including the historical glucose assay, have well-controlled strengths and limitations, determining their indications in clinical use. They all request high quality preanalytical and analytical methodologies, necessitating a strict evaluation of their performances by external quality control assessment trials. Specific requirements are needed for point-of-care testing technologies. This general overview, which describes how old and new tools of diabetes mellitus biological survey have evolved over the last decade, has been built through the prism of papers published in during this period.
自20世纪60年代末被发现以来，血红蛋白A（HbA）已被证明是糖尿病筛查和诊断的主要生物标志物。其他生物标志物也已通过经典实验室方法或更具创新性的非侵入性方法得以描述。所有糖尿病生物标志物，包括传统的血糖检测，都有其优势和局限性，这决定了它们在临床应用中的适用情况。它们都需要高质量的分析前和分析方法，因此需要通过外部质量控制评估试验对其性能进行严格评估。即时检测技术有特定要求。本综述描述了过去十年中糖尿病生物学检测的新旧工具是如何发展的，它是通过这一时期发表的论文视角构建而成的。
